Terms: = Head and neck cancer AND FLT4, FLT41, 2324, ENSG00000037280, P35916, VEGFR3, PCL AND Treatment
44 results:
1. Efficient Colon cancer Immunogene Therapy Through Co-Delivery of IL-22BP mRNA and Tumor Cell Lysate by CLSV Nanoparticles.
Huang J; Wang K; Fu X; Zhu M; Chen X; Gao Y; Ma P; Duan X; Men K
Int J Nanomedicine; 2023; 18():8059-8075. PubMed ID: 38164262
[TBL] [Abstract] [Full Text] [Related]
2. LncRNA H19 promotes tumor angiogenesis in smokers by targeting anti-angiogenic miRNAs.
Shirvaliloo M
Epigenomics; 2023 Jan; 15(2):61-73. PubMed ID: 36802727
[TBL] [Abstract] [Full Text] [Related]
3. Local and Systemic Delivery of the BimS Gene Nano-Complex for Efficient Oral Squamous Cell Carcinoma Therapy.
Ma P; Li J; Gao Y; Wu J; Men K; Li C; Men Y; Duan X
Int J Nanomedicine; 2022; 17():2925-2941. PubMed ID: 35814613
[TBL] [Abstract] [Full Text] [Related]
4. Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma.
Liu S; Knochelmann HM; Lomeli SH; Hong A; Richardson M; Yang Z; Lim RJ; Wang Y; Dumitras C; Krysan K; Timmers C; Romeo MJ; Krieg C; O'Quinn EC; Horton JD; Dubinett SM; Paulos CM; Neskey DM; Lo RS
Cell Rep Med; 2021 Oct; 2(10):100411. PubMed ID: 34755131
[TBL] [Abstract] [Full Text] [Related]
5. The levels of IL-6 and soluble IL-33R are increased in the renal vein during surgery for clear cell renal cell carcinoma.
Gudbrandsdottir G; Aarstad HH; Hjelle KM; Førde K; Reisæter L; Bostad L; Aarstad HJ; Beisland C
Cytokine; 2021 Aug; 144():155586. PubMed ID: 34058568
[TBL] [Abstract] [Full Text] [Related]
6. lncRNA‑MIAT facilitates the differentiation of adipose‑derived mesenchymal stem cells into lymphatic endothelial cells via the miR‑495/Prox1 axis.
Dai XW; Luo W; Lv CL
Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33760182
[TBL] [Abstract] [Full Text] [Related]
7. Stable Loading and Delivery of Icaritin Using PEG-pcl Micelles for Effective treatment of Oral Squamous Cell Carcinoma.
Yang JG; Zhang J; Chen XJ; Zhou G
Curr Drug Deliv; 2021; 18(7):975-983. PubMed ID: 33305705
[TBL] [Abstract] [Full Text] [Related]
8. Efficacy of axitinib in metastatic head and neck cancer with novel radiographic response criteria.
Swiecicki PL; Bellile EL; Brummel CV; Brenner JC; Worden FP
Cancer; 2021 Jan; 127(2):219-228. PubMed ID: 33079405
[TBL] [Abstract] [Full Text] [Related]
9. Glutathione-sensitive and folate-targeted nanoparticles loaded with paclitaxel to enhance oral squamous cell carcinoma therapy.
Fan L; Wang J; Xia C; Zhang Q; Pu Y; Chen L; Chen J; Wang Y
J Mater Chem B; 2020 Apr; 8(15):3113-3122. PubMed ID: 32207763
[TBL] [Abstract] [Full Text] [Related]
10. Nordic treatment practices survey and consensus for treatment of eyelid sebaceous carcinoma.
Leivo T; Sarmela J; Enckell-Aaltonen M; Dafgård Kopp E; Schmitt C; Toft PB; Sigurdsson H; Uusitalo M
BMC Ophthalmol; 2020 Mar; 20(1):103. PubMed ID: 32178641
[TBL] [Abstract] [Full Text] [Related]
11. Peptide P11 suppresses the growth of human thyroid carcinoma by inhibiting the PI3K/AKT/mTOR signaling pathway.
Wu D; Tian W; Li J; Zhang Q; Wang H; Zhang L; Xie Z; Ji A; Li Y
Mol Biol Rep; 2019 Jun; 46(3):2665-2678. PubMed ID: 31028568
[TBL] [Abstract] [Full Text] [Related]
12. Influence of buffy coat-derived putative endothelial progenitor cells on tumor growth and neovascularization in oral squamous cell carcinoma xenografts.
Otto M; Blatt S; Pabst A; Mandic R; Schwarz J; Neff A; Ziebart T
Clin Oral Investig; 2019 Oct; 23(10):3767-3775. PubMed ID: 30693401
[TBL] [Abstract] [Full Text] [Related]
13. The chromosome 11q13.3 amplification associated lymph node metastasis is driven by miR-548k through modulating tumor microenvironment.
Zhang W; Hong R; Li L; Wang Y; Du P; Ou Y; Zhao Z; Liu X; Xiao W; Dong D; Wu Q; Chen J; Song Y; Zhan Q
Mol Cancer; 2018 Aug; 17(1):125. PubMed ID: 30131072
[TBL] [Abstract] [Full Text] [Related]
14. treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT).
Wirth LJ; Tahara M; Robinson B; Francis S; Brose MS; Habra MA; Newbold K; Kiyota N; Dutcus CE; Mathias E; Guo M; Sherman SI; Schlumberger M
Cancer; 2018 Jun; 124(11):2365-2372. PubMed ID: 29656442
[TBL] [Abstract] [Full Text] [Related]
15. Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo.
Ferrari SM; Bocci G; Di Desidero T; Elia G; Ruffilli I; Ragusa F; Orlandi P; Paparo SR; Patrizio A; Piaggi S; La Motta C; Ulisse S; Baldini E; Materazzi G; Miccoli P; Antonelli A; Fallahi P
Oncol Rep; 2018 May; 39(5):2225-2234. PubMed ID: 29517103
[TBL] [Abstract] [Full Text] [Related]
16. Lenvatinib in the Therapy of Aggressive Thyroid cancer: State of the Art and New Perspectives with Patents Recently Applied.
Ferrari SM; Ruffilli I; Centanni M; Virili C; Materazzi G; Alexopoulou M; Miccoli M; Antonelli A; Fallahi P
Recent Pat Anticancer Drug Discov; 2018; 13(2):201-208. PubMed ID: 29468981
[TBL] [Abstract] [Full Text] [Related]
17. CAR T Therapy Targeting ICAM-1 Eliminates Advanced Human Thyroid Tumors.
Min IM; Shevlin E; Vedvyas Y; Zaman M; Wyrwas B; Scognamiglio T; Moore MD; Wang W; Park S; Park S; Panjwani S; Gray KD; Tassler AB; Zarnegar R; Fahey TJ; Jin MM
Clin Cancer Res; 2017 Dec; 23(24):7569-7583. PubMed ID: 29025766
[No Abstract] [Full Text] [Related]
18. Common
Lohavanichbutr P; Sakoda LC; Amos CI; Arnold SM; Christiani DC; Davies MPA; Field JK; Haura EB; Hung RJ; Kohno T; Landi MT; Liu G; Liu Y; Marcus MW; O'Kane GM; Schabath MB; Shiraishi K; Slone SA; Tardón A; Yang P; Yoshida K; Zhang R; Zong X; Goodman GE; Weiss NS; Chen C
Clin Cancer Res; 2017 Dec; 23(24):7550-7557. PubMed ID: 28974547
[No Abstract] [Full Text] [Related]
19. Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) Chemotherapy.
Smyth E; Zhang S; Cunningham D; Wotherspoon A; Soong R; Peckitt C; Valeri N; Fassan M; Rugge M; Okines A; Allum W; Stenning S; Nankivell M; Langley R; Tan P
Clin Cancer Res; 2017 Dec; 23(24):7543-7549. PubMed ID: 28972045
[No Abstract] [Full Text] [Related]
20. A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma.
Zauderer MG; Tsao AS; Dao T; Panageas K; Lai WV; Rimner A; Rusch VW; Adusumilli PS; Ginsberg MS; Gomez D; Rice D; Mehran R; Scheinberg DA; Krug LM
Clin Cancer Res; 2017 Dec; 23(24):7483-7489. PubMed ID: 28972039
[No Abstract] [Full Text] [Related]
[Next]
